Physician profile
Megan Devlin
NPI 1659654952
$2,589.74
in general payments reported to CMS, 2019-2025
17 companies · $265 in 2025
The $265 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $19.43 · 2023: $1,044 · 2024: $1,261 · 2025: $265.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,265 · Travel and Lodging: $1,247 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $31.00 · Education: $27.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,265.21 |
| Travel and Lodging | $1,247.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $31.00 |
| Education | $27.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $953.08 | 2024 | Axonics, Bulkamid |
| Medtronic, INC. | $913.08 | 2023-2024 | Interstim |
| Coloplast Corp | $184.42 | 2024 | |
| Boston Scientific Corporation | $178.50 | 2023-2025 | Axonics |
| Tolmar, INC. | $50.71 | 2024-2025 | Eligard, Rubraca, Jatenzo |
| Urogen Pharma, INC. | $45.12 | 2024-2025 | |
| Dentsply Ih Ab | $43.81 | 2025 | Lofric |
| Amgen INC. | $42.65 | 2024 | Repatha |
| Sumitomo Pharma America, INC. | $31.00 | 2024 | Gemtesa |
| Mimedx Group, INC. | $24.77 | 2025 | |
| Endo Pharmaceuticals INC. | $19.43 | 2022 | |
| C. R. Bard, INC. & Subsidiaries | $19.32 | 2025 | Bard Urinary Drainage Bag |
| Abc Home Medical Supply, INC. | $19.26 | 2025 | |
| Pharmaand Gmbh | $18.60 | 2025 | Rubraca |
| Azurity Pharmaceuticals, INC. | $17.72 | 2025 | Azmiro |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $15.51 | 2025 | Erleada |
| Phathom Pharmaceuticals, INC. | $12.76 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Megan Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.